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Abstract 
Psoriasis is a chronic inflammatory skin disease characterized by exaggerated 
keratinocyte proliferation. Current opinion indicates that psoriasis is driven by T cell-
mediated immune responses targeting keratinocytes. However, psoriasis cannot be explained 
solely on the basis of T-cell activation, and it is likely that an intrinsic alteration in epidermal 
keratinocytes plays a very important role in disease expression. Syndecans comprise a major 
family of cell surface heparan sulfate proteoglycans. Several studies indicate their role in 
adhesion, cell-extracellular matrix interactions, migration, keratinocyte proliferation and 
differentiation, inflammation, and wound healing. To determine the expression of syndecan-1 
in psoriasis, skin samples from 29 patients with fully developed psoriasis and skin samples 
from 14 healthy volunteer persons with no personal or family history of psoriasis were 
immunohistochemically examined using monoclonal antibody against syndecan-1. The 
expression of syndecan-1 was analyzed in whole mount section of psoriatic and non-psoriatic 
skin biopsies under high magnification (x400). In addition, the intensity and topography of 
reaction in the cell, as well as localization of positive cells in the epidermis were evaluated. 
Strong syndecan-1 reactivity in epidermal cells in all non-psoriatic and psoriatic samples was 
observed. Statistical analysis showed no significant differences between two analyzed groups 
(p>0.05). In normal skin syndecan-1 was expressed in full thickness of the epidermis. The 
strongest reaction was observed in membranes and intercellular junctions of spinous and 
granular layer while basal cells showed weaker expression that was confined to cytoplasm. In 
psoriatic skin syndecan-1 was expressed in the membrane and intercellular junction of cells 
located in thickened and elongated rete ridges of the epidermis. The strongest reaction was in 
basal and suprabasal layers and expression diminished through spinous layer. Cells in spinous 
layer loose syndecan-1 expression, which is opposite pattern to normal skin. Our results 
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suggest that aberrant skin expression of syndecan-1 may be involved in the development of 
psoriasis. 
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Psoriasis is a chronic inflammatory skin disease characterized by exaggerated 
keratinocyte proliferation. It is estimated that the prevalence of psoriasis varies from 1% to 
2% and increases with age. Current opinion indicates that psoriasis is driven by T cell-
mediated immune responses targeting keratinocytes. However, psoriasis cannot be explained 
solely on the basis of T-cell activation, and it is likely that an intrinsic alteration in epidermal 
keratinocytes plays a very important role in disease expression [4]. 
Syndecans comprise a major family of cell surface heparan sulfate proteoglycans. 
Syndecans at the cell surface function as coreceptors by binding to ligands and increasing 
ligand concentration in the pericellular vicinity of their signaling receptors. Several studies 
indicate their role in adhesion, cell-extracellular matrix interactions, migration, keratinocyte 
proliferation and differentiation, inflammation, and wound healing. In adult tissues, syndecan-
1 is predominantly expressed by epithelial cells and plasma cells, and expressed to a lesser 
degree by other cells types (e.g. fibroblasts, endothelial cells) [1]. 
To determine the expression of syndecan-1 in psoriasis, skin samples from 29 patients 
(17 female and 12 male, average age 47.3 years) with fully developed psoriasis and skin 
samples from 14 healthy volunteer persons (8 female and 6 male, average age 49.8 years) 
with no personal or family history of psoriasis were immunohistochemically examined using 
monoclonal antibody against syndecan-1 (CD138, clone MI15, dilution 1:25, DAKO, 
Denmark). Immunohistochemical analysis was performed following microwave streptavidin 
immunoperoxidase (MSIP) protocol on DAKO TechMateTM Horizon automated 
immunostainer (DAKO).  A sample of plasmacytoma that was strongly positive for syndecan-
1 was used as a positive control. The diagnosis of psoriasis was histologically confirmed in all 
cases and each specimen was re-evaluated by three pathologists (D.T., M.V. and B.K.). None 
of the patients had received any topical treatment for at least one month prior the study. Skin 
samples of both groups measured between 0.3 and 0.8 cm (average 0.54 cm). The expression 
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of syndecan-1 was analyzed in whole mount section of psoriatic and non-psoriatic skin 
biopsies under high magnification (x400). In addition, the intensity and topography of 
reaction in the cell, as well as localization of positive cells in the epidermis were evaluated. 
Statistical analysis was performed using χ2 test. The level of significance was set at p < 0.05. 
Strong syndecan-1 reactivity in epidermal cells in all non-psoriatic and psoriatic 
samples was observed (Table 1). Statistical analysis showed no significant differences 
between two analyzed groups (p>0.05). In addition, dermal appendages and some endothelial 
and inflammatory cells were also positive. In normal skin syndecan-1 was expressed in full 
thickness of the epidermis. The strongest reaction was observed in membranes and 
intercellular junctions of spinous and granular layer while basal cells showed weaker 
expression that was confined to cytoplasm (Fig. 1A). In psoriatic skin syndecan-1 was 
expressed in the membrane and intercellular junction of cells located in thickened and 
elongated rete ridges of the epidermis (Fig. 1B). The strongest reaction was in basal and 
suprabasal layers and expression diminished through spinous layer (Fig. 1C). Cells in most 
upper part of spinous layer showed no expression of syndecan-1 (Fig. 1D).  
 In our study, syndecan-1 was expressed in all samples of normal skin. The strongest 
reaction was in suprabasal, differentiating epidermal cells which are consistent with previous 
investigations [2,6,8]. To our knowledge there are no reports about expression of syndecan-1 
in psoriasis. We observed strong syndecan-1 expression in all 29 psoriatic samples but pattern 
of expression was different compared to normal skin. The strongest expression was in 
proliferating basal and suprabasal layers and expression diminished with cell differentiation. 
Cells in spinous layer loose syndecan-1 expression, which is opposite pattern to normal skin. 
 A role of syndecan-1 in wound healing, epidermal cell proliferation and migration is 
under extensive research [3,5,7,9]. Stepp and al. [9] recently reported that syndecan-1 
knockout mice display impaired proliferation and migration of corneal keratinocytes in eye 
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abrasion wound healing. The wounded syndecan-negative corneas failed to initiate 
proliferative burst 24 hours after wounding. In addition, the migration of corneal cells was 
hampered by the absence of syndecan-1 [9]. Elenius et al. [5] studied wound healing in mice 
that overexpress syndecan-1 in several tissues, including skin and blood. The elevated levels 
of shed syndecan-1 ectodomain in these animals inhibit booth re-epithelization and 
remodeling of the newly laid matrix in dermis [5]. Ojeh et al. [7] in our investigation showed 
role of syndecan-1 in regulation of keratinocytes proliferation during skin development and 
wound healing. They generated transgenic mice that overexpress syndecan-1 in the basal layer 
of the epidermis that harbors epidermal stem cells and transit amplifying cells. Transgenic 
mice exhibited hyperproliferative skin lesions that were characterized by normal cornified 
layer, occasional parakeratosis in the granular layer, and increased number of spinous cell 
layers. The number of suprabasal cell layers was increased and flattening and anucleation of 
the cells were delayed but terminal differentiation was preserved. The extent of the 
hyperproliferations varied between different skin locations and between individual mice. 
Some lesions also contained localized areas of remarkably thickened epidermis that involved 
some downgrowth into the dermis [7]. Similarities of lesion that exhibited transgenic mice 
with psoriatic lesion are remarkable. Increased number of suprabasal and spinous cell layers, 
delayed flattening and anucleation, parakeratosis, remarkably thickened epidermis with 
downgrowth into the dermis are all histological characteristic of psoriatic skin. In addition, in 
our investigation similar expression of syndecan-1 in psoriatic skin and transgenic mice was 
also observed. The strongest expression of syndecan-1 in psoriasis was in proliferative basal 
cell layer like in transgenic mice and expression diminished through spinous to cornified layer 
of the epidermis [7].  
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 Our results suggest that aberrant skin expression of syndecan-1 may be involved in the 
development of psoriasis. Further studies on larger patient series and in various stages of 
psoriatic lesions are welcome. 
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Table 1. The intensity of syndecan-1 expression in psoriatic and non-psoriatic skin 
 
 
 
 
 
 
 
 
 
*To evaluate the level of syndecan-1 expression, the percentage of positive cells and the staining intensity were graded on a 
scale of 0 – 3. Staining percentage was labeled as: 0 = 0% cells; 1 = 1- 33% positive cells; 2 = 34 – 66% positive cells; and 3 = 
more than 66% positive cells. Staining intensity was denoted as: 0 = no staining; 1 = weak staining; 2 = moderate staining; 3 = 
strong staining. For each sample, the staining percentage and staining intensity scores were multiplied to give staining index. 
Immunohistochemical staining index (ISI) was labeled as: 0 = zero; 1 – 3 = low; 4 – 6 = moderate; and 9 = high. 
 Psoriatic skin Non-psoriatic skin 
 
ISI 0* 
 
0 (0%) 
 
0 (0%) 
 
ISI 1* 
 
0 (0%) 
 
0 (0%) 
 
ISI 2* 
 
0 (0%) 
 
0 (0%) 
 
ISI 3* 
 
29 (100%) 
 
14 (100%) 
 
Total 
 
29 (100%) 
 
14 (100%) 
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Figure 1. (A) In non-psoriatic skin syndecan-1 was expressed in full thickness of the 
epidermis. The strongest reaction was observed in membranes and intercellular junctions of 
spinous and granular layer. The basal cells in non-psoriatic skin showed weaker expression of 
syndecan-1 that was confined to cytoplasm. (B) In psoriatic skin syndecan-1 was expressed in 
the membrane and intercellular junction of cells located in thickened and elongated rete ridges 
of the epidermis. (C) The strongest reaction was in basal and suprabasal layers and expression 
diminished through spinous layer. (D) Cells in most upper part of spinous layer in psoriatic 
skin showed no expression of syndecan-1. (The bar in B indicates 200 μm. A, C and D are of 
the same magnification, and bars indicate 50 μm.) 
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